Department of Health and Social Care

Vorasidenib

The Lord Bishop of St Albans: To ask His Majesty's Government what assessment they have made of theefficacy of Vorasidenib for the treatment of brain tumours.

Lord Markham: In the United Kingdom, medicines need to have a licence before they can be marketed, and these are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has not issued a scientific opinion for Vorasidenib. Should an application for Vorasidenib be received, the MHRA will consider this accordingly.

Health Services: Artificial Intelligence

Lord Clement-Jones: To ask His Majesty's Government what are the artificial intelligence (AI) applications funded to date under the NHS AI Lab's AI in Health and Care Awards; and how much each developer has received to date.

Lord Markham: The AI in Health and Care Award has provided £123 million to 86 AI technologies over three funding rounds. The Award is accelerating the testing and evaluation of the most promising AI technologies likely to meet the aims set out in the NHS Long Term Plan.These are live in more than 340 primary care networks and 40% of National Health Service acute trusts in England. The AI solutions are helping patients by supporting stroke diagnosis, cancer screening, cardiovascular monitoring and managing disease at home.The AI in Health and Care Award will not be considering any more funding applications, and all projects are set to complete either before or by 2025. The full list of the 86 projects and the developers granted funding from the AI in Health and Care Award is available in an online-only format on NHS England’s website.The funding allocated to projects that applied in the first two funding rounds is available in an online-only format at the Contracts Finder on GOV.uk. The funding provided to the nine projects for round three will be made available on the same website later this year.